Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.
In the past week, several companies reported results from clinical trials including Ascendis Pharma, Expres2ion and IO Biotech. Further, Saniona continued to soar with a 40% increase making the total return year-to-date more than 250% – probably due to invetors’ huge interst in new weight loss products.
Only 4 of the 20 listed, Danish biotech companies published news the past week. 11 of the 20 companies had a positive development in their share price for the week and 8 companies have had a positive share price performance year to date. Saniona is now the best performing stock this year.
Company news the past week
Ascendis Pharma
One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023 (Link)
No news the past week
Cessatech
No news the past week
CS MEDICA A/S Secures Future Compliance with New Medical Device Regulation through Signed Contract with Notify Body (Link)
CS MEDICA A/S Secures Trademark Approval in Canada (Link)
No news the past week
Evaxion Biotech
No news the past week
Expres2ion
12-month durability data announced for ABNCoV2 Phase II clinical trial (Link)
Fluoguide
No news the past week
Genmab
No news the past week
Gubra
No news the past week
Initiator Pharma
No news the past week
IO Biotech
IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone (Link)
Pila Pharma
No news the past week
Saniona
No news the past week
Scandion Oncology
No news the past week
SynAct Pharma
No news the past week
ViroGates
No news the past week
Zealand Pharma
No news the past week
Y-mAbs Therapeutics
The average 1-year price target among brokers that have issued a report on the stock in the last year is USD13.67. The stock is currently trading at USD7.58.
2cureX
No news the past week
SELECTED CASES
SHARE PRICE DEVELOPMENTS
On average, the Danish biotech stocks delivered a positive share price performance last week of 1.1%. In the past week, Saniona AB continued to reach new heights with a 40% increase, although the company did not report any company-specific news. CS Medica A/S followed with a 11% increase after it got trademark approval in Canada. On the other hand, Expres2ion Biotech Holding AB fell after they announced 12-month durability data for ABNCoV2, a COVID-19 booster vaccine. Curasight A/S, Zealand Pharma A/S and Saniona AB have been the best performing stocks year-to-date after soaring 108-256% after among other things partnerships and positive recommendations from authorities paving the way for approvals. The Danish biotech stocks have done great year-to-date with a total return of 15.9%.
Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment
Overview of share price developments the past week, year-to-date and last twelve months
